Alerts will be sent to your verified email
Verify Email
NECLIFE
|
Nectar Lifesciences
|
NGL Fine-Chem
|
Everest Organics
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
Number of ANDA's Filed in USA
|
15.0 . | n/a | n/a |
|
Global DMFs filed
|
101.0 . | n/a | n/a |
|
R&D as a % of Total Sales
|
0.85 % | 1.51 % | 1.13 % |
|
Financials
|
|||
|
5 yr Average ROE
|
-0.71 % | 18.84 % | 12.73 % |
|
5yr average Equity Multiplier
|
2.17 | 1.38 | 3.91 |
|
5yr Average Asset Turnover Ratio
|
0.74 | 1.06 | 1.13 |
|
5yr Avg Net Profit Margin
|
-0.63 % | 12.49 % | 2.92 % |
|
Price to Book
|
0.49 | 2.29 | 5.59 |
|
P/E
|
30.83 | 30.57 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
81.28 Days | 36.59 Days | -87.83 Days |
|
Inventory Days
|
136.26 Days | 49.75 Days | 61.25 Days |
|
Days Receivable
|
62.43 Days | 83.78 Days | 142.15 Days |
|
Days Payable
|
113.03 Days | 82.12 Days | 226.8 Days |
|
5yr Average Interest Coverage Ratio
|
0.94 | 24.92 | 3.02 |
|
5yr Avg ROCE
|
7.51 % | 25.51 % | 19.01 % |
|
5yr Avg Operating Profit Margin
|
7.57 % | 18.8 % | 6.68 % |
|
5 yr average Debt to Equity
|
0.73 | 0.17 | 0.84 |
|
5yr CAGR Net Profit
|
-31.15 % | 38.35 % | -58.15 % |
|
5yr Average Return on Assets
|
-0.34 % | 13.85 % | 3.96 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
44.53 % | 72.74 % | 61.09 % |
|
Share Pledged by Promoters
|
99.6 % | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-11.27 % | -1.07 % | -13.06 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Nectar Lifesciences
|
NGL Fine-Chem
|
Everest Organics
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|